Advances in Vaccines for Visceral Leishmaniasis
Author Information
Author(s): Krystal J. Evans, Lukasz Kedzierski
Primary Institution: The Walter and Eliza Hall Institute of Medical Research, The University of Melbourne
Hypothesis
The development of a vaccine for visceral leishmaniasis (VL) is a realistic public health goal.
Conclusion
The study summarizes advances in vaccination strategies against visceral leishmaniasis, highlighting the need for effective vaccines.
Supporting Evidence
- Visceral leishmaniasis accounts for the majority of mortality among leishmaniasis cases.
- Current treatment for VL is expensive and highly toxic, highlighting the need for a vaccine.
- 80 to 90% of human infections are asymptomatic, suggesting potential for vaccine development.
Takeaway
Scientists are trying to create a vaccine to protect people from a serious disease called visceral leishmaniasis, which is caused by a tiny bug. This disease can be very dangerous, but a vaccine could help keep people safe.
Methodology
The paper reviews various vaccination strategies and experimental models used to develop vaccines against visceral leishmaniasis.
Limitations
No single in vivo model accurately reflects all aspects of human VL disease, which complicates vaccine development.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website